STEERLife, a pioneer in pharmaceutical development technologies, and Callidus Research Laboratories, a formulation development services company, have partnered to accelerate drug development for global markets.
 
The collaboration combines STEERLife’s advanced Hot Melt Extrusion (HME) and Continuous Processing Technologies with Callidus’ Pharmaceutical Drug Development Expertise, addressing the global demand for innovative drug formulations and development.
 
By leveraging their combined strengths, STEERLife and Callidus will provide worldwide clients with advanced drug development services utilizing Hot Melt Extrusion (HME) technology. This partnership enables both organizations to integrate their specialized knowledge and skills, yielding innovative solutions and enhanced product offerings. Additionally, the collaboration facilitates network, contact, and market reach sharing, allowing both companies to enter new regions and customer segments. Jointly, they will meet the global demand for next-generation pharmaceutical formulations, serving generic and brand companies.
 
This partnership also enables end-to-end drug development for highly potent APIs. Beyond their complementary capabilities, the organizations’ collaboration is fueled by their shared commitment to pushing the boundaries of innovation to further futuristic product development for global markets.
 
“Our partnership with Callidus Research Laboratories represents a significant leap forward in pharmaceutical innovation,” said Indu Bhushan, CEO of STEERLife. “This collaboration empowers clients with cutting-edge technologies, extensive product development expertise, and seamless scale-up capabilities.”
 
“Partnering with STEERLife enhances our capabilities, allowing us to provide comprehensive, innovative solutions to pharmaceutical companies worldwide,” added Vardhaman Bafna, Co-founder & Director of Callidus Research Laboratories. “This collaboration exemplifies our dedication to pushing boundaries, fostering growth, and improving patient outcomes through transformative pharmaceutical solutions.”